Abstract
Albumin is widely conserved from vertebrates to invertebrates, and nature of mammalian albumins permit them to bind various endogenous ligands and drugs in the blood. It is known that at least two major ligand binding sites are present on the albumin molecule, which are referred to as Site I and Site II. These binding sites are thought to be almost completely conserved among mammals, even though the degree of binding to these sites are different depending on the physical and chemical properties of drugs and differences in the microenvironment in the binding pockets. In addition, the binding sites for medium and long-chain fatty acids are also well conserved among mammals, and it is considered that there are at least seven binding sites, including Site I and Site II. These bindings properties of albumin in the blood are also widely known to be important for transporting drugs and fatty acids to various tissues. It can therefore be concluded that albumin is one of the most important serum proteins for various ligands, and information on human albumin can be very useful in predicting the ligand binding properties of the albumin of other vertebrates.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allerton SE, Elwyn D, Edsalljt SP (1962) Isolation and amino acid composition of dog plasma albumin. J Biol Chem 237:85–88
Anraku M, Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M (2001) Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res 18(5):632–639
Anraku M, Kragh-Hansen U, Kawai K, Maruyama T, Yamasaki Y, Takakura Y, Otagiri M (2003) Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo. Pharm Res 20(4):684–692
Anraku M, Takeuchi K, Watanabe H, Kadowaki D, Kitamura K, Tomita K, Kuniyasu A, Suenaga A, Maruyama T, Otagiri M (2011) Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients. J Pharm Sci 100(9):3968–3976. https://doi.org/10.1002/jps.22571
Appleton DW, Sarkar B (1971) The absence of specific copper (II)-binding site in dog albumin a comparative study of human and dog albumins. J Biol Chem 246(16):5040–5046
Baret P, Le Sage F, Planesse C, Meilhac O, Devin A, Bourdon E, Rondeau P (2017) Glycated human albumin alters mitochondrial respiration in preadipocyte 3T3-L1 cells. BioFactors (Oxford, England) 43(4):577–592. https://doi.org/10.1002/biof.1367
Bhattacharya AA, Grune T, Curry S (2000) Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 303(5):721–732. https://doi.org/10.1006/jmbi.2000.4158
Blindauer CA, Harvey I, Bunyan KE, Stewart AJ, Sleep D, Harrison DJ, Berezenko S, Sadler PJ (2009) Structure, properties, and engineering of the major zinc binding site on human albumin. J Biol Chem 284(34):23116–23124
Bourdon E, Loreau N, Blache D (1999) Glucose and free radicals impair the antioxidant properties of serum albumin. FASEB J: Off Publ Fed Am Soc Exp Biol 13(2):233–244. https://doi.org/10.1096/fasebj.13.2.233
Brodersen R, Stern L (1980) Binding of bilirubin to albumin. CRC Crit Rev Clin Lab Sci 11(4):307–399
Brown WM, Dziegielewska KM, Foreman RC, Saunders NR (1989) Nucleotide and deduced amino acid sequence of sheep serum albumin. Nucleic Acids Res 17(24):10495. https://doi.org/10.1093/nar/17.24.10495
Bujacz A (2012) Structures of bovine, equine and leporine serum albumin. Acta Crystallogr D Biol Crystallogr 68(Pt 10):1278–1289. https://doi.org/10.1107/S0907444912027047
Chuang VT, Otagiri M (2006) Stereoselective binding of human serum albumin. Chirality 18(3):159–166. https://doi.org/10.1002/chir.20237
Chuang VT, Kuniyasu A, Nakayama H, Matsushita Y, Hirono S, Otagiri M (1999) Helix 6 of subdomain III A of human serum albumin is the region primarily photolabeled by ketoprofen, an arylpropionic acid NSAID containing a benzophenone moiety. Biochem Biophys Acta 1434(1):18–30. https://doi.org/10.1016/s0167-4838(99)00174-0
Coffer MT, Shaw CF III, Eidsness M, Watkins J, Elder R (1986) Reactions of auranofin and chloro (triethylphosphine) gold with bovine serum albumin. Inorg Chem 25(3):333–339
Collison KS, Parhar RS, Saleh SS, Meyer BF, Kwaasi AA, Hammami MM, Schmidt AM, Stern DM, Al-Mohanna FA (2002) RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 71(3):433–444
de Souza Pinto R, Castilho G, Paim BA, Machado-Lima A, Inada NM, Nakandakare ER, Vercesi AE, Passarelli M (2012) Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin. Lipids 47(5):443–450. https://doi.org/10.1007/s11745-011-3647-9
Diaz N, Suarez D, Sordo TL, Merz KM Jr (2001) Molecular dynamics study of the IIA binding site in human serum albumin: influence of the protonation state of Lys195 and Lys199. J Med Chem 44(2):250–260
Dixon JW, Sarkar B (1974) Isolation, amino acid sequence and copper(II)-binding properties of peptide (1-24) of dog serum albumin. J Biol Chem 249(18):5872–5877
Dugaiczyk A, Law SW, Dennison OE (1982) Nucleotide sequence and the encoded amino acids of human serum albumin mRNA. Proc Natl Acad Sci USA 79(1):71–75. https://doi.org/10.1073/pnas.79.1.71
Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P (2012) Human serum albumin: from bench to bedside. Mol Aspects Med 33(3):209–290. https://doi.org/10.1016/j.mam.2011.12.002
Hamilton JA (2013) NMR reveals molecular interactions and dynamics of fatty acid binding to albumin. Biochim Biophys Acta (BBA)-Gen Subj 1830(12):5418–5426
Hamilton JA, Era S, Bhamidipati SP, Reed RG (1991) Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin. Proc Natl Acad Sci USA 88(6):2051–2054. https://doi.org/10.1073/pnas.88.6.2051
He XM, Carter DC (1992) Atomic structure and chemistry of human serum albumin. Nature 358(6383):209–215. https://doi.org/10.1038/358209a0
Hilger C, Grigioni F, Hentges F (1996) Sequence of the gene encoding cat (Felis domesticus) serum albumin. Gene 169(2):295–296
Ho JX, Holowachuk EW, Norton EJ, Twigg PD, Carter DC (1993) X-ray and primary structure of horse serum albumin (Equus caballus) at 0.27-nm resolution. European journal of biochemistry 215(1):205–212. https://doi.org/10.1111/j.1432-1033.1993.tb18024.x
Horie T, Mizuma T, Kasai S, Awazu S (1988) Conformational change in plasma albumin due to interaction with isolated rat hepatocyte. Am J Physiol 254(4 Pt 1):G465–G470. https://doi.org/10.1152/ajpgi.1988.254.4.G465
Irikura M, Takadate A, Goya S, Otagiri M (1991) 7-Alkylaminocoumarin-4-acetic acids as fluorescent probe for studies of drug-binding sites on human serum albumin. Chem Pharm Bull 39(3):724–728
Ishima Y, Kragh-Hansen U, Maruyama T, Otagiri M (2009) Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications. Drug Metab Pharmacokinet 24(4):308–317
Jacobs S, Koj A (1969) Amino acid composition of rabbit plasma albumin and fibrin. Anal Biochem 27(1):178–182
Keita Y, Kratzer W, Worner W, Rietbrock N (1993) Effect of free fatty acids on the binding kinetics at the benzodiazepine binding site of glycated human serum albumin. Int J Clin Pharmacol Ther Toxicol 31(7):337–342
Kim J, Bronson CL, Hayton WL, Radmacher MD, Roopenian DC, Robinson JM, Anderson CL (2006) Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 290(2):G352–G360. https://doi.org/10.1152/ajpgi.00286.2005
Kobayashi K (2006) Summary of recombinant human serum albumin development. Biol: J Int Assoc Biol Stand 34(1):55–59. https://doi.org/10.1016/j.biologicals.2005.08.021
Kolthoff I, Willeford B Jr (1958) The interaction of copper(II) with bovine serum albumin1. J Am Chem Soc 80(21):5673–5678
Kosa T, Maruyama T, Otagiri M (1997) Species differences of serum albumins: I. Drug binding sites. Pharm Res 14(11):1607–1612
Kosa T, Nishi K, Maruyama T, Sakai N, Yonemura N, Watanabe H, Suenaga A, Otagiri M (2007) Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface. J Pharm Sci 96(11):3117–3124. https://doi.org/10.1002/jps.20887
Kragh-Hansen U (1981) Molecular aspects of ligand binding to serum albumin. Pharmacol Rev 33(1):17–53
Kragh-Hansen U (1988) Evidence for a large and flexible region of human serum albumin possessing high affinity binding sites for salicylate, warfarin, and other ligands. Mol Pharmacol 34(2):160–171
Kragh-Hansen U (1990) Structure and ligand binding properties of human serum albumin. Dan Med Bull 37(1):57–84
Kragh-Hansen U (1991) Octanoate binding to the indole- and benzodiazepine-binding region of human serum albumin. Biochem J 273(Pt 3):641–644. https://doi.org/10.1042/bj2730641
Kragh-Hansen U (2013) Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. Biochem Biophys Acta 1830(12):5535–5544. https://doi.org/10.1016/j.bbagen.2013.03.015
Kragh-Hansen U, Chuang VT, Otagiri M (2002) Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 25(6):695–704
Kurono Y, Kushida I, Tanaka H, Ikeda K (1992) Esterase-like activity of human serum albumin. VIII. Reaction with amino acid p-nitrophenyl esters. Chem Pharm Bull 40(8):2169–2172
Lawn RM, Adelman J, Bock SC, Franke AE, Houck CM, Najarian RC, Seeburg PH, Wion KL (1981) The sequence of human serum albumin cDNA and its expression in E. coli. Nucleic Acids Res 9(22):6103–6114. https://doi.org/10.1093/nar/9.22.6103
Losowsky M, Alltree E, Atkinson M (1962) Plasma colloid osmotic pressure and its relation to protein fractions. Clin Sci 22:249
Luiken JJ, Schaap FG, van Nieuwenhoven FA, van der Vusse GJ, Bonen A, Glatz JF (1999) Cellular fatty acid transport in heart and skeletal muscle as facilitated by proteins. Lipids 34(Suppl):S169–S175
Ma SF, Anraku M, Iwao Y, Yamasaki K, Kragh-Hansen U, Yamaotsu N, Hirono S, Ikeda T, Otagiri M (2005) Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites. Drug Metab Dispos: Biol Fate Chem 33(12):1911–1919. https://doi.org/10.1124/dmd.105.006163
Majorek KA, Porebski PJ, Dayal A, Zimmerman MD, Jablonska K, Stewart AJ, Chruszcz M, Minor W (2012) Structural and immunologic characterization of bovine, horse, and rabbit serum albumins. Mol Immunol 52(3–4):174–182. https://doi.org/10.1016/j.molimm.2012.05.011
Matejtschuk P, Dash CH, Gascoigne EW (2000) Production of human albumin solution: a continually developing colloid. Br J Anaesth 85(6):887–895. https://doi.org/10.1093/bja/85.6.887
Matsushita S, Isima Y, Chuang VT, Watanabe H, Tanase S, Maruyama T, Otagiri M (2004) Functional analysis of recombinant human serum albumin domains for pharmaceutical applications. Pharm Res 21(10):1924–1932
Matsuyama Y, Terawaki H, Terada T, Era S (2009) Albumin thiol oxidation and serum protein carbonyl formation are progressively enhanced with advancing stages of chronic kidney disease. Clin Exp Nephrol 13(4):308–315. https://doi.org/10.1007/s10157-009-0161-y
Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M (2005) The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 334(4):1322–1328. https://doi.org/10.1016/j.bbrc.2005.07.035
Murtiashaw MH, Winterhalter KH (1986) Non-enzymatic glycation of human albumin does not alter its palmitate binding. Diabetologia 29(6):366–370
Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A, Jinnouchi H, Anraku M, Kadowaki D, Ishima Y, Sasaki Y, Otagiri M, Maruyama T (2014) Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. PLoS ONE 9(1):e85216. https://doi.org/10.1371/journal.pone.0085216
Narazaki R, Harada K, Sugii A, Otagiri M (1997) Kinetic analysis of the covalent binding of captopril to human serum albumin. J Pharm Sci 86(2):215–219. https://doi.org/10.1021/js960234+
Oettl K, Marsche G (2010) Redox state of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol 474:181–195. https://doi.org/10.1016/s0076-6879(10)74011-8
Ohnishi K, Kawaguchi A, Nakajima S, Mori H, Ueshima T (2008) A comparative pharmacokinetic study of recombinant human serum albumin with plasma-derived human serum albumin in patients with liver cirrhosis. J Clin Pharmacol 48(2):203–208. https://doi.org/10.1177/0091270007310549
Otagiri M (2005) A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 20(5):309–323
Peters T (1966) All about Albumin: Biochemistry, Genetics, and Medical Application, Acad. Press, Orlando, FL:42
Peters T Jr (1970) Serum albumin. Adv Clin Chem 13:37–111
Peters T Jr (1985) Serum albumin. Adv Protein Chem 37:161–245
Peters T Jr, Blumenstock FA (1967) Copper-binding properties of bovine serum albumin and its amino-terminal peptide fragment. J Biol Chem 242(7):1574–1578
Petersen CE, Ha CE, Harohalli K, Feix JB, Bhagavan NV (2000) A dynamic model for bilirubin binding to human serum albumin. J Biol Chem 275(28):20985–20995. https://doi.org/10.1074/jbc.M001038200
Petitpas I, Grune T, Bhattacharya AA, Curry S (2001) Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol 314(5):955–960. https://doi.org/10.1006/jmbi.2000.5208
Reed RG (1986) Location of long chain fatty acid-binding sites of bovine serum albumin by affinity labeling. J Biol Chem 261(33):15619–15624
Reed RG, Burrington CM (1989) The albumin receptor effect may be due to a surface-induced conformational change in albumin. J Biol Chem 264(17):9867–9872
Reviewers CIGA (1998) Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ (Clin Res Ed) 317(7153):235–240. https://doi.org/10.1136/bmj.317.7153.235
Sadler PJ, Tucker A, Viles JH (1994) Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins. Comparison with Co2+, Cd2+ and Al3+. Eur J Biochem 220(1):193–200. https://doi.org/10.1111/j.1432-1033.1994.tb18614.x
Sakai T, Takadate A, Otagiri M (1995) Characterization of binding site of uremic toxins on human serum albumin. Biol Pharm Bull 18(12):1755–1761
Sakurama K, Kawai A, Tuan Giam Chuang V, Kanamori Y, Osa M, Taguchi K, Seo H, Maruyama T, Imoto S, Yamasaki K, Otagiri M (2018) Analysis of the binding of aripiprazole to human serum albumin: the importance of a chloro-group in the chemical structure. ACS Omega 3(10):13790–13797. https://doi.org/10.1021/acsomega.8b02057
Sakurama K, Nishi K, Imoto S, Hashimoto M, Komatsu T, Morita Y, Taguchi K, Otagiri M, Yamasaki K (2019) Further evidence regarding the important role of chlorine atoms of aripiprazole on binding to the site II area of human albumin. J Pharm Sci 108(5):1890–1895. https://doi.org/10.1016/j.xphs.2018.11.045
Sala-Trepat JM, Dever J, Sargent TD, Thomas K, Sell S, Bonner J (1979a) Changes in expression of albumin and alpha-fetoprotein genes during rat liver development and neoplasia. Biochemistry 18(11):2167–2178. https://doi.org/10.1021/bi00578a006
Sala-Trepat JM, Sargent TD, Sell S, Bonner J (1979b) alpha-Fetoprotein and albumin genes of rats: no evidence for amplification-deletion or rearrangement in rat liver carcinogenesis. Proc Natl Acad Sci USA 76(2):695–699. https://doi.org/10.1073/pnas.76.2.695
Sargent TD, Wu JR, Sala-Trepat JM, Wallace RB, Reyes AA, Bonner J (1979) The rat serum albumin gene: analysis of cloned sequences. Proc Natl Acad Sci USA 76(7):3256–3260. https://doi.org/10.1073/pnas.76.7.3256
Sekula B, Bujacz A (2015) Structural insights into the competitive binding of diclofenac and naproxen by equine serum albumin. J Med Chem 59(1):82–89
Sengupta S, Chen H, Togawa T, DiBello PM, Majors AK, Budy B, Ketterer ME, Jacobsen DW (2001) Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 276(32):30111–30117. https://doi.org/10.1074/jbc.M104324200
Sudlow G, Birkett DJ, Wade DN (1975) The characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 11(6):824–832
Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, Matsushima M, Nakayama M, Hosoya T, Era S (2004) Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 66(5):1988–1993. https://doi.org/10.1111/j.1523-1755.2004.00969.x
van Boekel MA, van den Bergh PJ, Hoenders HJ (1992) Glycation of human serum albumin: inhibition by diclofenac. Biochem Biophys Acta 1120(2):201–204. https://doi.org/10.1016/0167-4838(92)90270-n
van der Vusse GJ, Glatz JF, Stam HC, Reneman RS (1992) Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 72(4):881–940. https://doi.org/10.1152/physrev.1992.72.4.881
van der Vusse GJ, van Bilsen M, Glatz JF, Hasselbaink DM, Luiken JJ (2002) Critical steps in cellular fatty acid uptake and utilization. Mol Cell Biochem 239(1–2):9–15
Walker JE (1976) Lysine residue 199 of human serum albumin is modified by acetylsalicylic acid. FEBS Lett 66(2):173–175
Wanwimolruk S, Birkett DJ, Brooks PM (1982) Protein binding of some non-steroidal anti-inflammatory drugs in rheumatoid arthritis. Clin Pharmacokinet 7(1):85–92. https://doi.org/10.2165/00003088-198207010-00005
Watanabe H, Tanase S, Nakajou K, Maruyama T, Kragh-Hansen U, Otagiri M (2000) Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity. Biochem J 349(Pt 3):813–819. https://doi.org/10.1042/bj3490813
Watanabe H, Kragh-Hansen U, Tanase S, Nakajou K, Mitarai M, Iwao Y, Maruyama T, Otagiri M (2001) Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants. Biochem J 357(Pt 1):269–274. https://doi.org/10.1042/0264-6021:3570269
Watanabe H, Imafuku T, Otagiri M, Maruyama T (2017) Clinical implications associated with the posttranslational modification-induced functional impairment of albumin in oxidative stress-related diseases. J Pharm Sci 106(9):2195–2203. https://doi.org/10.1016/j.xphs.2017.03.002
Weijers RN (1977) Amino acid sequence in bovine serum albumin. Clin Chem 23(7):1361–1362
Yamada K, Yokomaku K, Kureishi M, Akiyama M, Kihira K, Komatsu T (2016) Artificial blood for dogs. Sci Rep 6:36782. https://doi.org/10.1038/srep36782
Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M (2003) Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int 63(2):464–473. https://doi.org/10.1046/j.1523-1755.2003.00752.x
Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M (1996) Characterization of site I on human serum albumin: concept about the structure of a drug binding site. Biochem Biophys Acta 1295(2):147–157. https://doi.org/10.1016/0167-4838(96)00013-1
Yamazaki E, Inagaki M, Kurita O, Inoue T (2005) Kinetics of fatty acid binding ability of glycated human serum albumin. J Biosci 30(4):475–481
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nishi, K., Yamasaki, K., Otagiri, M. (2020). Serum Albumin, Lipid and Drug Binding. In: Hoeger, U., Harris, J. (eds) Vertebrate and Invertebrate Respiratory Proteins, Lipoproteins and other Body Fluid Proteins. Subcellular Biochemistry, vol 94. Springer, Cham. https://doi.org/10.1007/978-3-030-41769-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-41769-7_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-41768-0
Online ISBN: 978-3-030-41769-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)